{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:33:20Z","timestamp":1783578800585,"version":"3.55.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,8,1]]},"DOI":"10.1093\/rheumatology\/kel147","type":"journal-article","created":{"date-parts":[[2006,6,17]],"date-time":"2006-06-17T00:39:41Z","timestamp":1150504781000},"page":"1029-1038","source":"Crossref","is-referenced-by-count":34,"title":["Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis"],"prefix":"10.1093","volume":"45","author":[{"given":"N. J.","family":"Bansback","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Barkham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. D.","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,6,16]]},"reference":[{"key":"key\n\t\t\t\t20171012061504_BIB1","doi-asserted-by":"crossref","unstructured":"Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ1986;5:1\u201330.","DOI":"10.1016\/0167-6296(86)90020-2"},{"key":"key\n\t\t\t\t20171012061504_BIB2","doi-asserted-by":"crossref","unstructured":"Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med2002;113:400\u20138.","DOI":"10.1016\/S0002-9343(02)01243-3"},{"key":"key\n\t\t\t\t20171012061504_BIB3","doi-asserted-by":"crossref","unstructured":"Kobelt G, Jonsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology2003;42:326\u201335.","DOI":"10.1093\/rheumatology\/keg107"},{"key":"key\n\t\t\t\t20171012061504_BIB4","doi-asserted-by":"crossref","unstructured":"Brennan A, Bansback NJ, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology2004;43:62\u201372.","DOI":"10.1093\/rheumatology\/keg451"},{"key":"key\n\t\t\t\t20171012061504_BIB5","doi-asserted-by":"crossref","unstructured":"Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis2005;64:995\u20131002.","DOI":"10.1136\/ard.2004.027565"},{"key":"key\n\t\t\t\t20171012061504_BIB6","doi-asserted-by":"crossref","unstructured":"Torre Alonso JC, Rodriguez PA, Arribas Castrillo JM, Ballina GJ, Riestra Noriega JL, Lopez LC. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Rheumatology1991;30:245\u201350.","DOI":"10.1093\/rheumatology\/30.4.245"},{"key":"key\n\t\t\t\t20171012061504_BIB7","doi-asserted-by":"crossref","unstructured":"Lebwohl M. Psoriasis. Lancet2003;361:1197\u2013204.","DOI":"10.1016\/S0140-6736(03)12954-6"},{"key":"key\n\t\t\t\t20171012061504_BIB8","doi-asserted-by":"crossref","unstructured":"Gladman DD.Psoriatic arthritis: recent advances in pathogenesis and treatment. Rheumatic Diseases Clinics of North America1992;18:247\u201356.","DOI":"10.1016\/S0889-857X(21)00721-3"},{"key":"key\n\t\t\t\t20171012061504_BIB9","doi-asserted-by":"crossref","unstructured":"O\u2019Neill T, Silman AJ. Psoriatic arthritis. Historical background and epidemiology. Baillieres Clin Rheumatol1994;8:245\u201361.","DOI":"10.1016\/S0950-3579(94)80017-0"},{"key":"key\n\t\t\t\t20171012061504_BIB10","unstructured":"Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol2001;28:1842\u20136."},{"key":"key\n\t\t\t\t20171012061504_BIB11","doi-asserted-by":"crossref","unstructured":"Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol2002;46:850\u201360.","DOI":"10.1067\/mjd.2002.119669"},{"key":"key\n\t\t\t\t20171012061504_BIB12","doi-asserted-by":"crossref","unstructured":"Fries JF, Spitz PW, Kraines RG. Measurement of patient outcome in arthritis. Arthritis Rheum1980;23:137\u201345.","DOI":"10.1002\/art.1780230202"},{"key":"key\n\t\t\t\t20171012061504_BIB13","doi-asserted-by":"crossref","unstructured":"Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum2003;48:1530\u201342.","DOI":"10.1002\/art.11024"},{"key":"key\n\t\t\t\t20171012061504_BIB14","doi-asserted-by":"crossref","unstructured":"Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum2003;48:2750\u201362.","DOI":"10.1002\/art.11439"},{"key":"key\n\t\t\t\t20171012061504_BIB15","doi-asserted-by":"crossref","unstructured":"Tijhuis GJ, de Jong Z, Zwinderman AH et al. The validity of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire. Rheumatology2001;40:1112\u20139.","DOI":"10.1093\/rheumatology\/40.10.1112"},{"key":"key\n\t\t\t\t20171012061504_BIB16","unstructured":"Blackmore MG, Gladman DD, Husted J, Long JA, Farewell VT. Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. J Rheumatol1995;22:886\u201393."},{"key":"key\n\t\t\t\t20171012061504_BIB17","doi-asserted-by":"crossref","unstructured":"Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Rheumatol1997;36:551\u20139.","DOI":"10.1093\/rheumatology\/36.5.551"},{"key":"key\n\t\t\t\t20171012061504_BIB18","unstructured":"Buxton MJ, Drummond MF, Van Hout BA et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ1998;7:741\u20132."},{"key":"key\n\t\t\t\t20171012061504_BIB19","doi-asserted-by":"crossref","unstructured":"Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum2004;50:2264\u201372.","DOI":"10.1002\/art.20335"},{"key":"key\n\t\t\t\t20171012061504_BIB20","doi-asserted-by":"crossref","unstructured":"Fraser AD, van Kuijk AW, Westhovens R et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis2005;64:859\u201364.","DOI":"10.1136\/ard.2004.024463"},{"key":"key\n\t\t\t\t20171012061504_BIB21","doi-asserted-by":"crossref","unstructured":"Kyle S, Chandler D, Griffiths CE et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology2005;44:390\u20137.","DOI":"10.1093\/rheumatology\/keh514"},{"key":"key\n\t\t\t\t20171012061504_BIB22","doi-asserted-by":"crossref","unstructured":"Kaltwasser JP, Nash J, Gladman D et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum2004;50:1939\u201350.","DOI":"10.1002\/art.20253"},{"key":"key\n\t\t\t\t20171012061504_BIB23","unstructured":"Crnkic M, Petersson I, Saxne T, Geborek P. Infiximab, etanercept and leflunomide in rheumatoid arthritis. Clinical experience in southern Sweden. Rheumatology2001;40:S82"},{"key":"key\n\t\t\t\t20171012061504_BIB24","doi-asserted-by":"crossref","unstructured":"Aletaha D, Stamm T, Kapral T et al. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis2003;62:944\u201351.","DOI":"10.1136\/ard.62.10.944"},{"key":"key\n\t\t\t\t20171012061504_BIB25","unstructured":"Mease PJ, Gottlieb AB, Yu EB, Dunn M, Woolley JM. Psoriatic Arthritis patients treated with etanercept experience sustained improvements in physical function. Ann Rheum Dis2005;64(Suppl 3):322."},{"key":"key\n\t\t\t\t20171012061504_BIB26","doi-asserted-by":"crossref","unstructured":"Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum1997;40:1868\u201372.","DOI":"10.1002\/art.1780401021"},{"key":"key\n\t\t\t\t20171012061504_BIB27","doi-asserted-by":"crossref","unstructured":"Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy2004;9:110\u20138.","DOI":"10.1258\/135581904322987535"},{"key":"key\n\t\t\t\t20171012061504_BIB28","doi-asserted-by":"crossref","unstructured":"Jobanputra P, Barton P, Bryan S, Burls A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess2002;6:1\u2013110.","DOI":"10.3310\/hta6210"},{"key":"key\n\t\t\t\t20171012061504_BIB29","unstructured":"National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal. (2004). Reference NO515. Available at http:\/\/www.nice.org.uk\/pdf\/TAP_Methods.pdf"},{"key":"key\n\t\t\t\t20171012061504_BIB30","doi-asserted-by":"crossref","unstructured":"Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics2000;17:479\u2013500.","DOI":"10.2165\/00019053-200017050-00006"},{"key":"key\n\t\t\t\t20171012061504_BIB31","doi-asserted-by":"crossref","unstructured":"Antoni C, Krueger GG, de Vlam K, Birbara et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis2005;64:1150\u20137.","DOI":"10.1136\/ard.2004.032268"},{"key":"key\n\t\t\t\t20171012061504_BIB32","doi-asserted-by":"crossref","unstructured":"Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum2005;52:3279\u201389.","DOI":"10.1002\/art.21306"},{"key":"key\n\t\t\t\t20171012061504_BIB33","doi-asserted-by":"crossref","unstructured":"Symmons DPM. Anti-tumour necrosis factor \u03b1 therapy: can we afford it?. Ann Rheum Dis2005;64:969\u201370.","DOI":"10.1136\/ard.2005.037564"},{"key":"key\n\t\t\t\t20171012061504_BIB34","unstructured":"Husted JA, Gladman DD, Cook RJ, Farewell VT. Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis. J Rheumatol1998;25:2146\u201355."}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/45\/8\/1029\/10652226\/kel147.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T13:31:44Z","timestamp":1627479104000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/rheumatology\/article\/45\/8\/1029\/1784891\/Estimating-the-cost-and-health-status-consequences"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,16]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2006,6,16]]},"published-print":{"date-parts":[[2006,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kel147","relation":{},"ISSN":["1462-0332","1462-0324"],"issn-type":[{"value":"1462-0332","type":"electronic"},{"value":"1462-0324","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,8]]},"published":{"date-parts":[[2006,6,16]]}}}